title: Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD.
abstract: The effects of the long-acting beta(2)-agonist formoterol, the anticholinergic drug oxitropium bromide, and their combination were compared in 16 patients with partially reversible stable COPD. On each of 4 study days patients inhaled both drugs separated by 180 min in alternate sequence, with formoterol being administered in two doses (formoterol 12 microg + oxitropium bromide 200 microg; oxitropium bromide 200 microg + formoterol 12 microg; formoterol 24 microg + oxitropium bromide 200 microg; oxitropium bromide 200 microg + formoterol 24 microg). FEV(1)and FVC were measured baseline and after 30, 60, 120, 180, 210, 240, 300 and 360 min. In terms of onset of action, formoterol performed better than oxitropium bromide. Within the first 180 min after inhalation formoterol 24 microg was the most effective drug (maximal change in FEV(1): formoterol 24 microg = 25.6%, formoterol 12 microg = 21.1%, oxitropium bromide = 18.2%). Increased bronchodilation was obtained when the second drug was added, the sequence formoterol 24 microg + oxitropium bromide being the most effective (maximal change in FEV(1)over baseline: formoterol 24 microg + oxitropium bromide 28.8%, oxitropium bromide + formoterol 24 microg 20.9%, formoterol 12 microg + oxitropium bromide 26.6%, oxitropium bromide + formoterol 12 microg 22.5%). Significant improvement in pulmonary function may be achieved by giving two different bronchodilators in stable COPD patients. The sequence formoterol 24 microg + oxitropium bromide 200 microg seems to be the most effective.
authors.affiliation: <<S. Maugeri>> Foundation, Institute of Care and Research, Veruno Medical Centre of Rehabilitation, Veruno (NO), Italy. mcazzola@qubisoft.it
authors.forename: M
authors.initials: M
authors.lastname: Cazzola
authors.forename: F
authors.initials: F
authors.lastname: Di Perna
authors.forename: C
authors.initials: C
authors.lastname: Califano
authors.forename: A
authors.initials: A
authors.lastname: Vinciguerra
authors.forename: M
authors.initials: M
authors.lastname: D'Amato
mesh_terms: D000280:Administration, Inhalation; D000368:Aged; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage* / Q000494:pharmacology; D012602:Scopolamine Derivatives / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D001993:Bronchodilator Agents; D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C017590:oxitropium